Search

Search Constraints

You searched for: Author/Creator Dillman, Robert

Search Results

1. 319 Phase II trial of immunotherapy in primary glioblastoma: antigens from self-renewing autologous tumor cells presented by autologous dendritic cell vaccine. (9th November 2020)

2. 319 Phase II trial of immunotherapy in primary glioblastoma: antigens from self-renewing autologous tumor cells presented by autologous dendritic cell vaccine. (9th November 2020)

3. ATIM-28. PHASE II TRIAL OF AV-GBM-1 (AUTOLOGOUS DENDRITIC CELLS LOADED WITH TUMOR ASSOCIATED ANTIGENS) AS ADJUNCTIVE THERAPY FOLLOWING SURGERY PLUS CONCURRENT CHEMORADIATION IN NEWLY DIAGNOSED GBM PATIENTS. (11th November 2019)

4. CTIM-26. PATIENT-SPECIFIC DENDRITIC CELL VACCINE (DC-ATA) PULSED WITH ANTIGENS FROM SELF-RENEWING AUTOLOGOUS TUMOR CELLS IN THE TREATMENT OF NEWLY-DIAGNOSED GLIOBLASTOMA: A PHASE II TRIAL. (9th November 2020)

5. CTIM-33. PHASE II TRIAL OF VACCINE IMMUNOTHERAPY IN PRIMARY GLIOBLASTOMA: ADJUNCTIVE AUTOLOGOUS DENDRITIC CELLS PULSED WITH LYSATE FROM IRRADIATED SELF-RENEWING AUTOLOGOUS TUMOR CELLS (AV-GBM-1). (12th November 2021)

6. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B positive patients with hepatocellular carcinoma. (6th November 2014)

8. Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines. Issue 2 (December 2015)

9. Surgery, Concurrent Radiation Therapy and Chemotherapy Followed by Injections of Autologous Dendritic Cell Vaccines Pulsed With Wntigens From Self-renewing Autologous Tumor Cells in the Treatment of Primary Glioblastoma. (16th November 2020)